Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | F3 | P13726 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | NQO2 | P16083 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598785 | 1.00 | NFE2L2 (0.65) | NFE2L2CYP1A2CYP2C9HSD17B3HSD11B1 | |
| SCHEMBL10021716 | 0.91 | MMP1 (0.65) | NFE2L2CYP1A2CYP2C9HSD17B3MAOA | |
| SCHEMBL4554033 | 0.88 | FOS (0.61) | NFE2L2CYP1A2CYP2C9HSD17B3PLIN1 | |
| SCHEMBL4554032 | 0.88 | FOS (0.61) | NFE2L2CYP1A2CYP2C9HSD17B3PLIN1 | |
| SCHEMBL4554034 | 0.88 | FOS (0.61) | NFE2L2CYP1A2CYP2C9HSD17B3PLIN1 | |
| SCHEMBL7654865 | 0.86 | NFE2L2 (0.63) | NFE2L2CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL79650 | 0.86 | NFE2L2 (0.63) | NFE2L2CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL79651 | 0.86 | NFE2L2 (0.63) | NFE2L2CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL30337035 | 0.86 | NFE2L2 (0.63) | NFE2L2CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL27674511 | 0.86 | NFE2L2 (0.63) | NFE2L2ALDH1A1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2022-05-19 | — | — | US | disclosed |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | TRUJILLO KRISTINA (US) | 2022-01-27 | — | — | US | disclosed |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | K&K BIOTECH (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| US-10751330-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-25 | — | — | US | disclosed |
| US-10744124-B2 | Human therapeutic agents | ANKH LIFE SCIENCES LIMITED (IE) | 2020-08-18 | — | — | US | disclosed |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | ANKH LIFE SCIENCES LIMITED (IE) | 2020-05-14 | — | — | US | disclosed |
| EP-3275465-B1 | THERAPEUTIC COMPOSITIONS COMPRISING A COMBINATION OF A HARMINE AND ISOVANILLIN COMPONENT | ANKH LIFE SCIENCES LTD (IE) | 2020-05-06 | — | — | EP | disclosed |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2020-03-03 | — | — | US | disclosed |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | ANKH LIFE SCIENCES LIMITED (IE) | 2019-11-12 | — | — | US | disclosed |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | STC.UNM | 2015-01-08 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841326-B2 | Therapeutic curcumin derivatives | STC.UNM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20070060644-A1 | Therapeutic curcumin derivatives | STC.UNM | 2007-03-15 | — | — | US | disclosed |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | STC.UNM | 2006-12-07 | — | — | US | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10744124-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | NFE2L2 832/4885CYP1A2 2166/4885CYP2C9 3818/4885 |
| US-20070060644-A1 | Therapeutic curcumin derivatives | FABP2, GLS2, FABP1 | NFE2L2 75/4885CYP1A2 2544/4885CYP2C9 3299/4885 |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | NFKBIA, IKBKB, NFKB2 | NFE2L2 9/4885CYP1A2 2168/4885CYP2C9 3441/4885 |
| US-10751330-B2 | Human therapeutic agents | INMT, HNMT, HASPIN | NFE2L2 832/4885CYP1A2 2166/4885CYP2C9 3818/4885 |
| US-20150011494-A1 | THERAPEUTIC CURCUMIN DERIVATIVES | FABP2, GLS2, FABP1 | NFE2L2 75/4885CYP1A2 2544/4885CYP2C9 3299/4885 |
| US-20220152001-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885CYP1A2 2166/4885CYP2C9 3818/4885 |
| US-10471049-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | NFE2L2 1139/4885CYP1A2 1507/4885CYP2C9 2400/4885 |
| US-20200147061-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885CYP1A2 2166/4885CYP2C9 3818/4885 |
| US-20200383958-A1 | HUMAN THERAPEUTIC AGENTS | INMT, HNMT, HASPIN | NFE2L2 832/4885CYP1A2 2166/4885CYP2C9 3818/4885 |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | KEAP1, NFE2L2, NQO1 | NFE2L2 2/4885CYP1A2 1921/4885CYP2C9 3562/4885 |
| US-10576067-B2 | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof | INMT, HNMT, COMT | NFE2L2 1139/4885CYP1A2 1507/4885CYP2C9 2400/4885 |
| US-20060276536-A1 | Cancer treatment using curcumin derivatives | BRCA1, VHL, TP53 | NFE2L2 5/4885CYP1A2 760/4885CYP2C9 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.